Previous 10 | Next 10 |
2022 and Recent Highlights: Full-year 2022 revenues of $88.6 million, up 22% over full-year 2021 revenues of $72.5 million Sold all non-ophthalmology assets, making Harrow a pure-play ophthalmic pharmaceutical company FDA approval of IHEEZO™ topical ocular anesthetic CMS ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 13, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm,...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 23, 2023, after the market close. The Company will also post its fourth quarter Letter to St...
Summary Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands their customers, solves their pain points, and has earned their trust. This is a deep moat. The company was built by founder/CEO Mark Baum from zero to a dominant positio...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - February 22, 2023) - Faruqi & Faruqi, LLP, a leading national securities law fi...
Summary Harrow is a slow and steady seller of various ophthalmic products. In the last few months, it has gone up considerably. I expect more from the company, although I am still trying to figure out their strengths and weaknesses. I covered Harrow Health ( HROW )...
Harrow Health Inc. ( NASDAQ: HROW ) fell 4.8% after a new short report from Bonitas Research about the eyecare pharmaceutical company. Bonitas claims that company has issues with "risks disclosures" and "quality control standards," according to the report. Bonitas said it's sh...
Summary SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP appreciated 35.31% during 2022. 2023 stock market returns will be determined by the direction of earnings. Dear Partners, SRK Fund I, LP apprec...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...